No.12-78

November 29, 2012
Eisai Co., Ltd.

EISAI TO PRESENT NEW RESEARCH ON HALAVEN® AT 35TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that new clinical study results on the company's novel anticancer agent Halaven® (generic name: eribulin mesylate) will be presented during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The symposium will be held December 4-8, 2012, in San Antonio, Texas in the United States.

The studies highlight Eisai's current and ongoing research efforts to establish the clinical benefits of Halaven and maximize the drug's value. This year's SABCS will also include an oral presentation on December 7 highlighting the results of a head-to-head study of Halaven versus capecitabine (Study 301) that was conducted in 1,102 patients with locally advanced or metastatic breast cancer who were previously treated with anthracyclines and taxanes with the aim of expanding Halaven's contribution to patients at an earlier stage in the treatment of their disease. All studies to be presented highlight the company's current oncology product portfolio strategy and research accomplishments in this field.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

The following Eisai abstracts are accepted for presentation at this year's SABCS:

Product	**Abstract name and scheduled presentation date and time (local time)**
Halaven® (eribulin mesylate) Session: **S6-6**	A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes ***Oral Presentation*** | December 7 (Fri), 16:30-16:45
Halaven® (eribulin mesylate) Abstract no: **P1-12-02**	Results of a Phase II, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer ***Poster Session*** | December 5 (Wed), 17:00-19:00
Halaven® (eribulin mesylate) Abstract no: **P5-20-04**	Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a Phase II, multicenter, single-arm study ***Poster Session*** | December 7 (Fri), 17:00-19:00

(Continued of following page)

Halaven® (eribulin mesylate) Abstract no: **P1-13-11**	Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a Phase II, single-arm feasibility study ***Poster Session*** | December 5 (Wed), 17:00-19:00
Halaven® (eribulin mesylate) Abstract no: **P6-11-14**	Post-hoc safety and tolerability assessment in patients receiving palliative radiation during treatment with eribulin mesylate for metastatic breast cancer ***Poster Session*** | December 8 (Sat), 7:00-8:30
N/A Abstract no: **P6-09-06**	Family members' burden in patients with metastatic and early stage breast cancer ***Poster Session*** | December 8 (Sat), 7:00-8:30

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120